ProQR Therapeutics N.V. (PRQR) stock
PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.15−0.03 (-2.54%)
Close on Nov 17, 2026Market cap $121.17MP/E –Yield –
ProQR Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
ProQR Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -233.4%. For fiscal 2025 it was -273.1%, against -161.2% the year before. The highest annual figure on record is -161.2% in fiscal 2024.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -273.1% | −112.0 |
| FY2024 | Dec 31, 2024 | -161.2% | +327.9 |
| FY2023 | Dec 31, 2023 | -489.1% | +1323.9 |
| FY2022 | Dec 31, 2022 | -1813.0% | +2472.4 |
| FY2021 | Dec 31, 2021 | -4285.4% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -100.7% | +220.2 |
| Q1 FY2026 | Mar 31, 2026 | -671.4% | −432.0 |
| Q4 FY2025 | Dec 31, 2025 | -194.0% | +40.0 |
| Q3 FY2025 | Sep 30, 2025 | -391.5% | −164.7 |
| Q2 FY2025 | Jun 30, 2025 | -320.9% | −263.8 |
| Q1 FY2025 | Mar 31, 2025 | -239.3% | −57.9 |
| Q4 FY2024 | Dec 31, 2024 | -234.1% | −43.2 |
| Q3 FY2024 | Sep 30, 2024 | -226.8% | +312.7 |
| Q2 FY2024 | Jun 30, 2024 | -57.1% | +674.1 |
| Q1 FY2024 | Mar 31, 2024 | -181.5% | +1252.0 |
| Q4 FY2023 | Dec 31, 2023 | -190.9% | +1539.7 |
| Q3 FY2023 | Sep 30, 2023 | -539.5% | +1895.8 |
| Q2 FY2023 | Jun 30, 2023 | -731.2% | +971.2 |
| Q1 FY2023 | Mar 31, 2023 | -1433.4% | +74.9 |
| Q4 FY2022 | Dec 31, 2022 | -1730.6% | +5519.7 |
| Q3 FY2022 | Sep 30, 2022 | -2435.3% | −765.9 |
| Q2 FY2022 | Jun 30, 2022 | -1702.4% | +3731.0 |
| Q1 FY2022 | Mar 31, 2022 | -1508.3% | – |
| Q4 FY2021 | Dec 31, 2021 | -7250.2% | – |
| Q3 FY2021 | Sep 30, 2021 | -1669.4% | – |
| Q2 FY2021 | Jun 30, 2021 | -5433.3% | – |
See a number that looks wrong?